14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ACST ranks #17417 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Acasti Pharma Stock Forecast NASDAQ:ACST

$1.17 (-9.30%)

Volume: 531k

Closed: Dec 03, 2021

Hollow Logo Score: -7.869

Acasti Pharma Stock Forecast

$1.17 (-9.30%)

Volume: 531k

Closed: Dec 03, 2021

Score Hollow Logo -7.869
Which way will ACST go? Request
Key Stats
Beta 2.16
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] The Acasti Pharma stock currently holds an RSI14 at 22 and is oversold on RSI14. The stock being oversold is no guarantee for instant reaction up as some stocks may be oversold for a long time. It is important to review the previous RSI-history to get an indication of the RSI-sensitiveness.

Volatile ride for Acasti Pharma stock price on Friday moving between $1.15 and $1.30
(Updated on Dec 03, 2021)

Sell candidate since 2021-11-16 Loss -24.03%

The Acasti Pharma stock price fell by -9.30% on the last day (Friday, 3rd Dec 2021) from $1.29 to $1.17. During the day the stock fluctuated 13.04% from a day low at $1.15 to a day high of $1.30. The price has fallen in 6 of the last 10 days and is down by -16.43% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -569 thousand shares and in total, 531 thousand shares were bought and sold for approximately $620.85 thousand.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -38.72% during the next 3 months and, with a 90% probability hold a price between $0.66 and $0.94 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

There are few to no technical positive signals at the moment. The Acasti Pharma stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $1.32 and $1.58. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Wednesday, October 20, 2021, and so far it has fallen -35.00%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

Support, Risk & Stop-loss

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.15 between high and low, or 13.04%. For the last week the stock has had a daily average volatility of 8.74%.

Acasti Pharma is oversold on RSI14 (22). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Acasti Pharma stock A Buy?

Acasti Pharma holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.

Current score: -7.869

Predicted Opening Price for Acasti Pharma of Monday, December 6, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 6, 2021 Current price
$1.21 $1.17 (Undervalued)
Strong Sell Candidate Downgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

B. Riley does not see either upside or downside right now giving ACST "Buy - Neutral" on their last update on Sep 01, 2020. The price target was changed from $2.00 to $0.50.

Volatility and Risk
Daily Average Volatility: 8.74 %
Overall Risk: Very High High Medium Low Very Low
8.74 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $1.29
Price: $1.17
No Support Found

ACST Insider Trading Show all Trades


Last 8 transactions
Buy: 1 441 800 | Sell: 0 (Shares)
Date Action Amount Person Type
Nov 12, 2021 Buy 42 100 Canan John Stock Options (Right to Buy)
Nov 12, 2021 Buy 42 100 Carter Roderick Noel Stock Options (Right to Buy)
Nov 12, 2021 Buy 655 500 D'alvise Janelle Stock Options (Right to Buy)
Nov 12, 2021 Buy 287 900 Ford Brian D. Stock Options (Right to Buy)
Nov 12, 2021 Buy 42 100 Haseltine William A Stock Options (Right to Buy)
Show all Insider Trades

Last 8 transactions
Buy: 1 441 800 | Sell: 0 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 1.36 15.95 %
1.30 11.06 %
1.26 8.03 %
Current price: 1.17
Support 1.15 -1.76 %
1.11 -4.79 %
1.06 -9.69 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 1.40 19.66 %
1.34 14.53 %
1.29 10.26 %
Current price 1.17
Support 0 .
0 .
0 .

Click to get the best stock tips daily for free!

About Acasti Pharma

Acasti Pharma Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of various cardiometabolic disorders primarily abnormalities in blood lipids. The company offers Onemia, a medical food product for the dietary management of omega-3 phospholipids deficiency, and related abnormal lipid profiles and cardiometabolic disorders. It also develops CaPre, a prescription drug candida... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE